http://www.lsis.com/goto/r95/rss 2010-06-23T11:10:55+01:00 text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FB%1Cu%7Dy PRINCETON, N.J. & WILMINGTON, Del.-(BUSINESS WIRE)-Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo. The study also showed reductions in the secondary endpoint of fasting plasma glucose (FPG) and total body weight compared to placebo in these patients. Signs, symptoms and other reports suggestive of urinary (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FB%1Cxx%7C BACKGROUND: The contribution of various risk factors to the burden of stroke worldwide is unknown, particularly in countries of low and middle income. We aimed to establish the association of known and emerging risk factors with stroke and its primary subtypes, assess the contribution of these risk factors to the burden of stroke, and explore the differences between risk factors for stroke and myocardial infarction. METHODS: We undertook a standardised case-control study in 22 countries worldwide between March 1, 2007, and April 23, 2010. Cases were patients with acute first stroke (within 5 days of symptoms onset and 72 h of hospital admission). Controls had no history of stroke, and were (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v95/%3B%97f%FB%11ux%7F UroToday.com - Combining radical radiotherapy with targeted drugs: a new primary treatment for aggressive prostate cancer? Current treatment results for prostate cancer are at an excellent level. According to the Finnish Cancer Registry, relative five-year survival rates for patients with prostate cancer followed between 2003-2005 are at 89% (Dec 12th 2009). However, prostate cancer is still the second leading cause of male cancer death, after lung cancer. Aggressive prostate cancer and / or cancer that has spread beyond the prostate capsule tends to recur regardless of the choice of primary treatment (radiation therapy or surgery). Combining radical radiotherapy with targeted drugs has (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v95/%3B%97f%FB%11%7B%7By Reuters - AstraZeneca PLC (AZN.L) has agreed to pay $103 million to settle U.S. litigation involving claims the drugmaker inflated prices for its Zoladex cancer drug and Pulmicort Respules asthma medicine. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v95/%3B%97f%FB%14%7Ex%7C News outlets report on the pharmaceutical industry and a new requirement by the Food and Drug Administration. The Washington Post: "The Food and Drug Administration this week began posting online the results of safety evaluations of recently approved drugs and vaccines. The action follows a law enacted in 2007 that requires the agency to provide more safety information to consumers and health professionals. The evaluations must be conducted 18 months after a new drug comes on the market. Rare and sometimes serious side effects are often discovered only when a drug is used by a much larger and more varied group of patients than exposed to it in clinical trials leading to its approval. FDA (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FC%1C%7Fw%7C We have investigated the scope and limitations of a method for predicting the regioisomer distribution in electrophilic aromatic substitution reactions that are under kinetic control. This method is based on calculation of the relative stabilities of the sigma-complex intermediates using density functional theory. Predictions from this method can be used quantitatively for halogenations; it agreed to an accuracy of about 1 kcal/mol with experimental observations in 10 of the 11 investigated halogenation reactions. For nitrations, the method gave useful predictions for heterocyclic substrates. The method failed for nitration of monosubstituted benzenes, and we expect that more elaborate (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FC%12%7D%7Bz LANSDALE, Pa.-(BUSINESS WIRE)-Microsoft Corp. has named Merck and Company, Inc. and ProtonMedia winners of the company s Life Sciences Innovation Awards 2010. The awards, announced at the Drug Information Association s (DIA) 46th annual meeting in Washington, D.C., were given in recognition of innovative solutions in the pharmaceutical and life sciences industry. The awards honor companies that have demonstrated the successful application of available software and devices to revolutionize medicine, bring therapeutic breakthroughs to market faster, fight serious ailments, improve health, and enhance people s quality of life. Microsoft recognized Merck s innovative use of ProtonMedia s (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FC%16%7Dx%7F Elevated Src family kinase (SFK) activity is associated with tumor invasion and metastasis. The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking. Saracatinib is likely to be used clinically in combination regimens, specifically with 5-fluorouracil (5-FU) and oxaliplatin, in CRC. The aim of this study was to determine the effect of saracatinib on oxaliplatin and 5-FU efficacy in CRC cells. Saracatinib did not modulate 5-FU efficacy but antagonized oxaliplatin in a schedule-specific manner through reduced oxaliplatin uptake via an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FC%16%7Dy%7E Ticagrelor (AZD6140) is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes. The pharmacokinetics, metabolism, and excretion of ticagrelor were investigated over 168 h in 6 healthy male subjects receiving a single oral suspension dose of [(14)C]-ticagrelor 200 mg. Ticagrelor was rapidly absorbed with a maximum plasma concentration at 1.5 h. The major active metabolite, AR-C124910XX, is formed by O-deethylation. Exposure to AR-C124910XX was 29% of peak and 40% of overall exposure to ticagrelor. In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FC%17%7Dx%7D A simple, rapid and robust high-throughput assay for the quantitative analysis of metformin in plasma from different species using laser diode thermal desorption interfaced with atmospheric chemical pressure ionization tandem mass spectrometry (LDTD-APCI-MSMS) was developed for use in a pharmaceutical discovery environment. In order to minimize sample preparation a generic protein precipitation method was used to extract metformin from the plasma. Laser diode thermal desorption is a relatively new sample introduction method, the optimization of the instrumental parameters are presented. The method was successfully applied to spiked mouse, rat, dog and human plasma samples and was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FC%14%7E%7Fz The Efectividad de un Programa de Intervención en el Control de la Presión Arterial de los Hipertensos en Riesgo de Desarrollar Insuficiencia Cardiaca (HEROIC) study was designed to assess whether an educational program for primary care physicians could improve blood pressure (BP) control in hypertensive patients at high risk for developing heart failure. The program contained a combination of educational training (live group sessions or online training) and information feedback. Two hundred twenty-six physicians completed the program and provided valid data in 2489 patients before and 2168 after 1 year. There was a small but significant reduction of -1.1 mm Hg (P=.009) in systolic BP (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v95/%3B%97f%FD%1Ct%7E%7C Reuters - Generic competition to AstraZeneca's (AZN.L) top-selling acid reflux drug Nexium moved a step closer in Canada, after a court rejected the drugmaker's bid to stop a copycat version from entering the market. text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v95/%3B%97f%FD%1Cz%7B%7D Highlighted Links Blue Chip Patient Recruitment NORTHBROOK, IL-(Marketwire - June 15, 2010) - Blue Chip, an independent, full-service global marketing agency, announced today the launch of Blue Chip Patient Recruitment (BCPR), a division dedicated to serving pharmaceutical and biotech clients with clinical trial recruitment marketing. This new division reflects Blue Chip's 15 years of continued growth in patient recruitment and leverages the resources of a full-service agency with deep expertise in direct response media, retail brand marketing and clinical site recruitment management. BCPR's first client is BioSante Pharmaceuticals, Inc. "We are pleased to launch the new division with a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FD%1D%7Dvs BACKGROUND: This work evaluates pregnancy and infant loss in 1,069 vehicle-treated cynomolgus monkeys from 78 embryo-fetal development (EFD) studies and 14 pre-postnatal development (PPND) studies accrued during 1981-2007. METHODS: Losses were analysed by survival function and hazard ratio using logistic regression for influence of year, study type (e.g., dose duration), and test item route of administration (ig, im, iv, sc). RESULTS: Neither study type nor route of dosing affected pregnancy outcome. Losses were higher pre-1990 (104 losses/347 pregnancies) compared to 1990 onwards (94 losses/722 pregnancies). Losses were greatest before gestation day 50 and at parturition. Using post-1989 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FD%13%7Dv%7B Angew Chem Int Ed Engl. |-| Butters M, Harvey JN, Jover J, Lennox AJ, Lloyd-Jones GC, Murray PM. |-| AstraZeneca, Severn Road, Hallen, Bristol BS10 7ZE (UK). text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FD%11%7Exs WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding ¢ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today ( œUppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced ), UMC s new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug Dictionary Enhanced is the world s most comprehensive dictionary of medicinal product information and the de facto standard for coding (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FD%11%7Ez%7F WASHINGTON-(BUSINESS WIRE)-SAS Drug Development has long enabled organizations to focus resources on efficiently developing drugs rather than building complex clinical technology infrastructures. Now, this mature, powerful solution from SAS, the leader in business analytics, features a host of innovations and enhancements that include an integrated workflow system to automate development processes and an improved SAS programming environment designed for seasoned SAS experts. After working closely with SAS and reviewing early versions, it s clear that SAS truly listened to its customers and understands the value of partnering with the industry, getting value from users involved daily in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FD%16z%7Fz The identification of chemokines and their receptors as potent mediators of leukocyte infiltration raised interest in the potential role of these proteins on disease pathogenesis. This is exemplified by the chemokine receptor, CCR1, which has been shown to be up-regulated in a number of human diseases, the implications of which have been suggested by animal models where inhibition of CCR1 or its ligands have shown beneficial effects. These data support the possibility that a CCR1 antagonist will provide therapeutic benefit to patients with inflammatory diseases. Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FE%1Cu%7Fr LEXINGTON, Mass.-(BUSINESS WIRE)-Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct. Cubist filed a patent infringement lawsuit against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FE%1Cyv%7B PURPOSE: Reversible mean increases in serum creatinine (approx. 10%) have been observed during clinical investigations of the oral direct thrombin inhibitor AZD0837. The aim of this study was to evaluate whether the increase in s-creatinine is due to a decrease in renal glomerular filtration rate (GFR) or an inhibition of the tubular secretion of creatinine. METHODS: Thirty healthy subjects aged 60-71 years were enrolled in an open-label, randomised, placebo-controlled, two-way crossover study (D1250C00033) in which they received AZD0837 450 mg extended-release formulation once daily for 8 days. Cimetidine was co-administered on Days 6-8 during both treatment periods. Blood and urine (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v95/%3B%97f%FE%12y%7C%7F Highlighted Links ValueTrak Product Information ValueCentric Home Page ORCHARD PARK, NY-(Marketwire - June 9, 2010) - More than 100 pharmaceutical manufacturers gathered in Marco Island, Florida, for the annual ValueCentric User Conference. Actual, accurate and actionable data was the theme this year as ValueCentric showcased their ability to integrate Trade Channel and Prescription data in one application, an industry first! "As the industry continues to face challenges with projected or estimated data, we now have the ability to deliver actual prescription data that is integrated directly with direct trade channel data, providing a view from shipments into the supply chain through (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FE%12%7D%7E%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2ddbd5/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in China" report to their offering. Favorable economic conditions are expected to continue to boost the growth of the pharmaceutical industry in China. The health of the pharmaceutical industry has been improving continuously since 2000 and is expected to get even better. The Chinese pharmaceuticals market is forecast to become the world's fifth largest by 2010 - and the largest by 2050. There are still greater market access following China's entry into the World Trade Organization (WTO), multinational investors (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FE%12%7C%7D%7B WATERTOWN, Mass.-(BUSINESS WIRE)-Wolfe Laboratories, Inc. (WLI), a biopharmaceutical development services company dedicated to community service, participated in the first-ever statewide Biotechnology Job Shadow Day by hosting twenty 11th grade students from the Boston Latin School, the oldest school in America. The future of the biotechnology industry in Massachusetts is dependent upon the presence of a qualified workforce "The partnership between the biotech industry and Massachusetts future workforce is extremely important to Wolfe Laboratories, so we were thrilled to participate in the first-ever statewide Biotechnology Job Shadow Day,  said Margarita Hunter, Head of Marketing and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FE%13uw%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/122efb/looking_at_the_can) has announced the addition of the "Looking at the Cancer Therapy Market" report to their offering. Cancer is a disease characterized by a population of cells that grow and divide without respect to normal limits, invade and destroy adjacent tissues, and may spread to distant anatomic sites through a process called metastasis. These life-threatening, malignant properties of cancers differentiate them from benign tumors, which are self-limited in their growth and do not invade or metastasize. Cancer may affect people at all ages, but risk for the more common varieties tends to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FE%13uy%7C SHEFFIELD, England-(BUSINESS WIRE)-Simcyp Limited today announces that it has released the latest version of its flagship simulator, further cementing its position as the industry leader in modelling and simulation of drug-drug interactions (DDIs) in virtual populations. The enhanced features in Version 10.0 of the Simcyp Population-based ADME Simulator have been implemented in accordance with the priorities set by the leading pharmaceutical companies which make up the Simcyp Consortium. The new developments expand Simcyp s DDI capabilities to include transporter interactions and provide the flexibility to use clinical inputs in DDI predictions. This is in line with many of the recent (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FE%16z%7Fx The application of high-content imaging in conjunction with multivariate clustering techniques has recently shown value in the confirmation of cellular activity and further characterization of drug mode of action following pharmacologic perturbation. However, such practical examples of phenotypic profiling of drug response published to date have largely been restricted to cell lines and phenotypic response markers that are amenable to basic cellular imaging. As such, these approaches preclude the analysis of both complex heterogeneous phenotypic responses and subtle changes in cell morphology across physiologically relevant cell panels. Here, we describe the application of a cell-based (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FE%16%7Ey%7C In the 1990s, the breast cancer drug trastuzumab (Herceptin; Genentech/Roche) - an antibody specific for human epidermal growth factor receptor 2 (HER2; also known as ERBB2) - was approved based on trials in which HER2 expression levels were used to select patients in clinical trials. This provided support for analogous efforts for drugs that target the epidermal growth factor receptor (EGFR). However, the development of these drugs, such as cetuximab (Erbitux; Bristol-Myers Squibb/Lilly) and gefitinib (Iressa; AstraZeneca), has revealed that EGFR expression is an insufficient and unreliable biomarker to select patients for EGFR-targeted therapies in both lung and colon cancer. Indeed, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FE%17%7Fy%7B Objective. Budesonide/formoterol inhalation aerosol (Symbicort(R) AstraZeneca, Wilmington, Delaware) is an inhaled corticosteroid (ICS) and long-acting beta(2)-adrenergic agonist (LABA) combination administered twice daily via one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) approved in the United States for the long-term maintenance treatment of persistent asthma in patients /=12 years of age whose asthma cannot be controlled by an ICS alone. The objective was to review efficacy, safety, and pharmacogenetic data on budesonide/formoterol pMDI in the treatment of persistent asthma. Methods. The authors searched PubMed and respiratory meeting databases to identify asthma (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v95/%3B%97f%FE%15%7Bw%7E Reuters - India's Dr Reddy's Laboratories (REDY.BO) has got tentative approval from U.S. regulators to launch the generic version of AstraZeneca's (AZN.L) Accolate, used to treat asthma, a company spokesman said on Wednesday. text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v95/%3B%97f%FE%15%7Bxy All public secondary students throughout BC will now have access to lifesaving CPR skills thanks to a donation of more than 3,500 CPR mannequins from AstraZeneca Canada, sanofi-aventis and Pfizer Canada. The donation of $500,000 goes to the ACT Foundation, a national charitable organization with a mandate to establish the CPR program in secondary schools across Canada. The donation extends the program to more than 80 additional BC schools bringing the total coverage to over 260 schools in BC. It also increases the number of BC students trained from 34,000 a year to 48,000 a year. For more information please visit www.actfoundation.ca. Photo by Kevin Hill. RICHMOND, BRITISH (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v95/%3B%97f%FE%15%7B%7Cr RICHMOND, BRITISH COLUMBIA-(Marketwire - June 8, 2010) - Thanks to a $500,000 contribution from pharmaceutical leaders AstraZeneca Canada, Pfizer Canada and sanofi-aventis, the lifesaving ACT High School CPR Program opportunity can now be extended to all BC public secondary schools. Currently, 180 BC public secondary schools have been set up with ACT High School CPR Program. Thanks to this generous donation, over 80 more BC public secondary schools can now receive the program. With this new support the number of students trained each year is expected to jump from 34,000 to 48,000 and teachers trained will go from 675 to over 1,000. The funds will purchase and distribute 3,555 CPR (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FE%15y%7E%7C LANSDALE, Pa.-(BUSINESS WIRE)-IBM (NYSE: IBM) and ProtonMedia have entered into a teaming agreement that will result in the delivery of innovative, 3-D virtual collaboration and communication solutions engineered specifically for global life sciences organizations. Under the terms of the agreement, ProtonMedia s ProtoSphere technology will be the basis for customized, 3-D virtual collaboration environments to create high-performance workplaces. IBM s Global Business Services division will provide consultancy, integration, deployment, and installation services to life science customers around the world, leveraging the ProtoSphere platform. The companies are also in discussions for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FE%15x%7Ez LEXINGTON, Mass.-(BUSINESS WIRE)-Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. District Court for the District of Delaware issued a claim construction order in the litigation between Cubist and Teva. The Order is linked at the end of this news release. Cubist filed a patent infringement lawsuit against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. The complaint alleges infringement of US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016. About CUBICIN CUBICIN (daptomycin for injection) is approved in the U.S. and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v95/%3B%97f%FF%12xx%7D WILMINGTON, Del., June 2 /PRNewswire-FirstCall/ - Today, the U.S. Food and Drug Administration (FDA) released final label revisions for respiratory medications that contain an active ingredient known as a long-acting beta-agonist (LABA). This follows the FDA communication on 18 February 2010 requesting all manufacturers of LABA-containing medications to undertake class-labeling changes. The FDA made label revisions to both single ingredient and combination LABA-containing medications. For the treatment of asthma, single ingredient LABAs should only be used with an asthma controller medication such as an inhaled corticosteroid (ICS), they should not be used alone. SYMBICORT (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v95/%3B%97f%FF%12%7Fv%7C RICHMOND, BRITISH COLUMBIA-(Marketwire - June 7, 2010) - DATE: Tuesday, June 8th, 2010 TIME: 10 a.m. WHERE: Richmond Secondary School 7171 Minoru Blvd Richmond, British Columbia V6Y 1Z3 WHAT: The ACT Foundation, along with AstraZeneca Canada, Pfizer Canada and sanofi-aventis will announce a major province-wide donation in support of the lifesaving ACT High School CPR Program. This announcement will feature a mock emergency where BC public secondary students will rescue a cardiac arrest victim using their CPR skills. As well, a class of 30 students will participate in a CPR training demonstration and more than 200 donated training mannequins, of the 3500 to be donated, will be on site. (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v95/%3B%97f%FF%12%7Fv%7F RICHMOND, COLOMBIE-BRITANNIQUE-(Marketwire - 7 juin 2010) - DATE : Mardi 8 juin 2010 HEURE : 10 h Oà : Richmond Secondary School 7171, boulevard Minoru Richmond (Colombie-Britannique) V6Y 1Z3 QUOI : La Fondation ACT ainsi que AstraZeneca Canada, Pfizer Canada et sanofi-aventis feront l'annonce d'un don important visant à soutenir le Programme de RCR au secondaire d'ACT dans l'ensemble de la province. Lors de cet événement, il y aura une simulation d'urgence durant laquelle des élèves du secondaire public de C.-B. mettront en pratique leurs connaissances en RCR en venant en aide à une victime d'un arrêt cardiaque. Aussi bien, une classe de 30 élèves participera à (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FF%12%7D%7B%7E IRVINE, Calif.-(BUSINESS WIRE)-Allergan, Inc. (NYSE: AGN) has received CEO Cancer Gold Standard ¢ accreditation, recognizing the organization s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace. do something bold and venturesome about cancer within your own corporate families. William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard ¢, in collaboration with the National Cancer Institute, many of its (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FF%13tx%7E CHICAGO-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting. The data were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois. Through our broad ongoing clinical (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FF%11%7Ewz LEXINGTON, Mass.-(BUSINESS WIRE)-Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. District Court for the District of Delaware notified Cubist that the Markman hearing previously scheduled for June 9, 2010 has been cancelled. The court stated that a claim construction order will issue in due course. Cubist filed a patent infringement lawsuit against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. The complaint alleges infringement of US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016. About CUBICIN CUBICIN (daptomycin (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97f%FF%15tv%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f8bc26/option_and_evaluat) has announced the addition of the "Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition" report to their offering. Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97f%FF%15%7Dx%7F Am J Psychiatry. |-| Ashton AK. |-| Dr. Ashton serves on the speaker's bureaus of AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Merck, PamLab, Pfizer, Sanofi-Aventis, Sepracor, and Symposia Medicus. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v95/%3B%97g%F6%12%7Byz Reuters - U.S. health regulators have finalized new warnings for controversial inhaled asthma drugs, but exercised new powers to order the changes on products made by GlaxoSmithKline Plc and AstraZeneca Plc. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v95/%3B%97g%F6%12%7Bxx GAITHERSBURG, Md., June 2 /PRNewswire/ - MedImmune today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants. The committee's recommendation will be considered by FDA reviewers in their evaluation of the Biologics License Application (BLA) for motavizumab. "We continue to believe motavizumab offers a meaningful clinical benefit to patients at high risk for a very common and serious illness," said Genevieve Losonsky, M.D., vice president, clinical development, (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v95/%3B%97g%F6%12zzs NEW YORK, NY-(Marketwire - June 2, 2010) - ExL Pharma's 6th Public Relations and Communications Summit for Pharmaceutical, Biotech and Medical Technology Communicators is taking place this summer at the Pfizer World Headquarters on July 26-27, 2010 in New York, New York. This leading event, which is well attended by communications professionals in pharmaceutical, biotech and medical device companies, features two full days of expert-led presentations, networking opportunities, and interactive sessions. Attendees will gain concrete strategies for success in the marketplace and improved patient outcomes through strengthened communications. *Register before June 11, 2010 to save $200 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97g%F6%12x%7F%7B ST. LOUIS-(BUSINESS WIRE)-Amerinet Inc., a leading national healthcare group purchasing organization (GPO) announced the winners of its 2009 Supplier Performance and Amerinet Choice member awards. This highlights Amerinet s ability to drive volume as well as the highest quality and performance of our suppliers products œThe Amerinet Supplier Performance Awards offer an opportunity for us to recognize those manufacturers, distributors and service providers that met the highest standards of excellence in 2009. Each of them found innovative ways to supply Amerinet members with quality products and services, delivered with outstanding performance and valued customer service,  said Dale (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97g%F6%12%7Fxr BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics website, www.seattlegenetics.com, under the œInvestor and News  section. Jefferies 2010 Global Life Sciences ConferenceTuesday, June 8, 20101:00 p.m. Eastern TimeNew York, NY 9th Annual Needham Healthcare ConferenceWednesday, June 9, 20108:40 a.m. Eastern TimeNew York, NY 31st Annual Goldman Sachs Healthcare ConferenceTuesday, June 15, 20103:05 p.m. Pacific TimeLos Angeles, CA (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v95/%3B%97g%F6%12%7Ev%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ed89f5/a_decision_support) has announced the addition of the "A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market" report to their offering. A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v95/%3B%97g%F6%13y%7Fx The aim of this study was to measure 11beta-HSD-1 activity in subcutaneous adipose tissue by an ex vivo method in three subgroups; lean, obese, and type 2 diabetes subjects, both in the fasting state and after a mixed meal and to determine the variability and reproducibility of this method. Eighteen subjects were investigated; 6 lean, 6 abdominally obese, and 6 type 2 diabetes subjects (BMI 22+/-1, 30+/-3 and 31+/-3 kg/m (2), respectively). Needle biopsies were taken repeatedly and an index of 11beta-HSD-1 activity was measured as percent conversion of (3)H-cortisone to (3)H-cortisol/100 mg tissue. For two separate biopsies taken in the fasting state on the same day, the within subjects CV (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v95/%3B%97g%F6%10%7Fw%7D The Food and Drug Administration (FDA), USA has denied approval of AstraZeneca's Axanum (aspirin plus esomeprazole magnesium) and an expanded indication for AstraZeneca's Nexium (esomeprazole magnesium). AstraZeneca received a CRL (Complete Response Letter) for the new drug application for Axanum tablets, as well as a CRL for the supplemental new drug application (sNDA) for Nexium. In a press release, AstraZeneca says it is evaluating the CRLs and will continue discussions with the FDA to decide on the next steps for the two medications. The company said it will respond to the FDA's request for additional information. Both applications were submitted by AstraZeneca to the FDA on April (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v95/%3B%97g%F6%10%7Fy%7B AstraZeneca announced the top-line results of the HORIZON II Phase III study evaluating RECENTIN (cediranib) for the first-line treatment of metastatic colorectal cancer (mCRC). Cediranib met the co-primary endpoint of improving progression-free survival (PFS) but showed no improvement in overall survival (OS). The adverse events associated with cediranib during this study were broadly consistent with previous studies. HORIZON II is the second of two pivotal studies of cediranib in first-line mCRC. In March, the HORIZON III study of cediranib plus chemotherapy versus bevacizumab plus chemotherapy did not meet the primary endpoint of PFS. Based on the results of these two trials, (…)